Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Equity Ratio (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Equity Ratio for 10 consecutive years, with 0.54 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 143.92% year-over-year to 0.54, compared with a TTM value of 0.54 through Dec 2025, up 143.92%, and an annual FY2025 reading of 0.54, up 143.92% over the prior year.
  • Equity Ratio was 0.54 for Q4 2025 at Zevra Therapeutics, up from 0.49 in the prior quarter.
  • Across five years, Equity Ratio topped out at 25.91 in Q2 2022 and bottomed at 0.47 in Q3 2022.
  • Average Equity Ratio over 5 years is 1.81, with a median of 0.49 recorded in 2025.
  • Peak annual rise in Equity Ratio hit 2651.88% in 2022, while the deepest fall reached 149.13% in 2022.
  • Year by year, Equity Ratio stood at 0.76 in 2021, then fell by 14.83% to 0.65 in 2022, then plummeted by 44.88% to 0.36 in 2023, then tumbled by 37.97% to 0.22 in 2024, then soared by 143.92% to 0.54 in 2025.
  • Business Quant data shows Equity Ratio for ZVRA at 0.54 in Q4 2025, 0.49 in Q3 2025, and 0.46 in Q2 2025.